Stockreport

Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control [Seeking Alpha]

Trevi Therapeutics, Inc.  (TRVI) 
PDF TRVI's valuation reflects optimism, but the risk/reward profile and funding gap ahead of IPF launch warrant caution; I maintain a Hold rating. Long-term efficacy, saf [Read more]